Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acotiamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acotiamide SCHEMBL29362154 | 0.99 | ACHE (0.98) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL27938245 | 0.99 | ACHE (0.98) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL30872102 | 0.99 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL28293346 | 0.99 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Acotiamide SCHEMBL1043131 | 0.99 | ACHE (1.00) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6973893 | 0.95 | ACHE (0.91) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6975742 | 0.95 | ACHE (0.91) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL27944898 | 0.94 | ACHE (0.88) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL6963022 | 0.93 | ACHE (0.86) | ACHELMNANPSR1HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL28208032 | 0.93 | ACHE (0.86) | ACHELMNANPSR1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518052-A | Preparation method of acotiamide hydrochloride impurity | 廊坊市泽康医药科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111440128-A | Preparation method of acotiamide hydrochloride impurity | 廊坊市泽康医药科技有限公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-2650277-B1 | METHOD FOR PRODUCING 2-BROMO-4,5-DIALKOXY BENZOIC ACID | ZERIA PHARM CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9096511-B2 | Method for producing 2-bromo-4,5-dialkoxy benzoic acid | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2650277-A1 | METHOD FOR PRODUCING 2-BROMO-4,5-DIALKOXY BENZOIC ACID | Zeria Pharmaceutical Co., Ltd. (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130253222-A1 | METHOD FOR PRODUCING 2-BROMO-4,5-DIALKOXY BENZOIC ACID | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| EP-0994108-B1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6197970-B1 | REACTING WITH SECONDARY OR TERTIARY AMINE; DEBLOCKING, DEPROTECTING | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0994108-A1 | PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253222-A1 | METHOD FOR PRODUCING 2-BROMO-4,5-DIALKOXY BENZOIC ACID | HAO2, HAAO, BBOX1 | ACHE 3526/4885LMNA 2835/4885NPSR1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.